Analysis of Effectiveness of THP-based Regimens in Treating 90 Cases of Hematopoietic Malignancies

VernacularTitle:吡柔比星联合化疗治疗血液系统恶性肿瘤90例临床观察
Author: Pu ZHAO
Publication Type:Journal Article
Keywords: Hematopoietic; Malignancy; THP(pirarubicin); Chemotherapy/Short-term response
From: Journal of Medical Research 2006;0(10):-
CountryChina
Language:Chinese
Abstract: Objective To observe the effect of Pirarubicin (THP) with other chemical agents in treating hematopoietic Malignancies. Methods 90 inpatients diagnosed as hematopoietic malignancies between January 2000 to December 2005 were treated with THP with other chemical agents. 30 had not been treated previously ,(untreated) while 60 were relapsing or resistant to previous treatment. Acute leukemia(AL) was 60 cases, Malignancy lymphoma(ML) was 21 cases, Multiple myeloma(MM) was 9 cases. Results The complete response(CR) rate among AL untreated and relapsing/resistant groups were 91.7% and 38.5%; 71.5% of response rate were malignancy Lymphoma(ML); 67.8% of response rate ware multiple myeloma(MM).The total response rate was 80.0%. The main side-effect of THP is bone marrow depression which led to fever and bleeding with rates 30.2%, 20.5%. The non-bone marrow side effects were tolerable. Damage to the liver was a prominent occurrence 20.8%. Conclusions THP was effective as the first line anti-tumor drug with other chemical agents in treating hematopoietic malignancies, its side-effects were mild and well tolerable.